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Generating human skeletal muscle models is instru-
mental for investigating muscle pathology and
therapy. Here, we report the generation of three-
dimensional (3D) artificial skeletal muscle tissue
from human pluripotent stem cells, including
induced pluripotent stem cells (iPSCs) from patients
with Duchenne, limb-girdle, and congenital muscular
dystrophies. 3D skeletal myogenic differentiation of
pluripotent cells was induced within hydrogels under
tension to providemyofiber alignment. Artificial mus-
cles recapitulated characteristics of human skeletal
muscle tissue and could be implanted into immuno-
deficient mice. Pathological cellular hallmarks of
incurable forms of severe muscular dystrophy could
be modeled with high fidelity using this 3D platform.
Finally, we show generation of fully human iPSC-
derived, complex, multilineage muscle models con-
taining key isogenic cellular constituents of skeletal
muscle, including vascular endothelial cells, peri-
cytes, and motor neurons. These results lay the
foundation for a human skeletal muscle organoid-
like platform for disease modeling, regenerative
medicine, and therapy development.INTRODUCTION
Skeletal muscle is the most abundant human tissue, and it is
responsible for movement, posture, temperature control, andC
This is an open access article undvarious metabolic functions. It is composed of aligned multinu-
cleated myofibers, and its repair and regeneration rely on resi-
dent stem or progenitor cells, of which satellite cells are the
best characterized (Tedesco et al., 2010). Nonetheless, impaired
muscle regeneration occurs in acute or chronic conditions, such
as significant trauma (Grogan et al., 2011), or incurable inherited
disorders, such as muscular dystrophies (Mercuri and Muntoni,
2013). Artificial human skeletal muscles would provide an
invaluable tool to study pathological mechanisms, test potential
therapeutics, and develop tissue replacement protocols. Use of
a similar approach in other tissues has proved transformational
for drug development and regenerative medicine by means
of organoid technology (Fatehullah et al., 2016; Lancaster and
Knoblich, 2014).
Although several studies have reported methods to engineer
rodent skeletal muscle tissue (Carosio et al., 2013; Corona et al.,
2014; Huang et al., 2005; Juhas et al., 2014; Machingal et al.,
2011;Shandalovet al., 2014;VanDusenetal., 2014), fewergroups
have used human cells (Chiron et al., 2012; Fuoco et al., 2015;
Maddenet al., 2015; Powell et al., 1999;Quarta et al., 2017; Tchao
et al., 2013). Apart from a recent study on healthy donor human
pluripotent stem cells (hPSCs) for muscle tissue engineering
(Rao et al., 2018), most studies used primary human cells from
invasive muscle biopsies, facing hurdles such as poor cell avail-
ability, limitedcell expansionpotential, and exhaustionof differen-
tiation ability. In addition, although there is an increasing need to
develop clinically relevant multilineage patient-specific models
(Giacomelli et al., 2017), no such isogenic human skeletal muscle
model has been derived to date. These obstacles hinder the
translational potential of these platforms for muscle diseases.
To overcome these limitations, here we have exploited
the virtually unlimited proliferative capacity and controllable dif-
ferentiation of human embryonic stem cells (hESCs) and humanell Reports 23, 899–908, April 17, 2018 ª 2018 The Author(s). 899
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Differentiation of Multiple hPSC Lines into Skeletal Myotubes and Remodeling of Fibrin Hydrogels upon 3D Culture
(A) Immunofluorescence analysis for myosin heavy chain (MyHC) in standard monolayer cultures of differentiated hESC- and hiPSC-derived cells (DMD,
Duchenne muscular dystrophy; LGMD2D, limb-girdle muscular dystrophy type 2D; LMNA, skeletal muscle laminopathies, specific mutations listed).
(B) Side-view of the 3D culture platform with freshly polymerized gels at day 0 (left) and day 10 (right) of culture containing hiPSC-derived myogenic cells.
(C) Representative phase contrast images of cellularized hydrogels after polymerization (day 0) and after 10 days in culture. Gels undergo remodeling, shorten,
and thin in culture (graph). Mean ± SD, N = 2–4 per time point.
(D) H&E staining of a transverse hydrogel sections after 10 days of differentiation.
Magnification: centronucleated myofibers. Scale bars: (A and D) 100 mm; (C) 1 mm.induced pluripotent stem cells (hiPSCs) (referred to collectively
as hPSCs) (Inoue et al., 2014) to produce 3D artificial skeletal
muscle constructs for complex muscle disease modeling.
hPSCs were induced to skeletal myogenesis within a biocom-
patible hydrogel using established protocols (Caron et al.,
2016; Maffioletti et al., 2015; Tedesco et al., 2012). Artificial mus-
cles could be made using hiPSCs from Duchenne, limb-girdle
type 2D, and LAMIN A/C (LMNA)-related muscular dystrophies.
Our 3D platform modeled cellular hallmarks of LMNA-related
muscular dystrophies with high fidelity. Finally, essential cell
types present in muscle tissue, such as vascular cells and motor
neurons, were derived from the same hiPSC source to generate
isogenic multilineage muscle constructs.
RESULTS
3D Artificial Muscles Can Be Generated from Multiple
Healthy and Dystrophic hPSC Lines
To generate 3D human artificial skeletal muscles, hPSC-derived
myogenic cells (healthy and dystrophic) (Figure 1A) were
embedded in fibrin hydrogels and differentiated, adapting a
cardiac tissue engineering platform (Hansen et al., 2010). Fibrin
was polymerized from fibrinogen in molds between two flexible
silicone posts providing continuous tension to the gel, sufficient
to direct orientation of cells along the force axis (Figure 1B). Over
10 days, cells remodeled the matrix, generating a 7–8 mm
long strip of tissue containing structures resembling skeletal
myofibers (Figures 1C, 1D, and S1A). Both transgene-based900 Cell Reports 23, 899–908, April 17, 2018(Maffioletti et al., 2015) and transgene-free (Caron et al., 2016)
differentiation protocols produced muscle constructs (Figures
2A and S1B). Transgene-based muscle constructs were gener-
ally used due to the better alignment of myofibers, easier scal-
ability of cultures, and experimental cost-effectiveness.
Immunolabeling of artificial muscles from hESCs and
hiPSCs—healthy donor, Duchenne muscular dystrophy (DMD),
limb-girdle muscular dystrophy type 2D (LGMD2D) (Figure S1C),
and LMNA-related muscular dystrophies—showed homoge-
neous presence of myosin heavy chain (MyHC)+ multinucleated
myotubes oriented along the force axis of the hydrogels (Figures
2A and 2B), as observed with primary human myoblasts within
the same platform (Figure S1D). Transverse sections of artificial
muscles revealed abundantMyHC+muscle fibers surrounded by
LAMININ+ extracellular matrix (Figure 2C). Western blot analysis
confirmed production of MyHC protein (Figure 2D). Healthy and
dystrophic muscle constructs also expressed markers
of skeletal muscle determination and maturation (e.g., MYOD
and DYSTROPHIN) (Figure 2E). Immunohistochemical staining
highlighted proteins associated with skeletal muscle maturation,
such as sarcomeric actin (Figure 2F). Electron microscopy
revealed that muscle constructs displayed some degree of
cytoskeletal organization into sarcomeres, the basic functional
unit of striated myofibers (Figure 2G). Functional myotubes
within the artificial muscles were detected by caffeine-induced
calcium transients (Figure S1E).
Pax7 marks a population of self-renewing myogenic stem
cells known as satellite cells (Tedesco et al., 2010). To assess
Figure 2. 3D Artificial Skeletal Muscle Constructs Derived from Healthy and Dystrophic hPSCs
(A) Whole-mount immunofluorescence for myosin heavy chain (MyHC) on muscle constructs derived from hESCs, WT hiPSCs (transgene-based and transgene-
free differentiation protocols) and dystrophic hiPSCs (DMD, LGMD2D, and skeletal muscle LMNA) differentiated in 3D for 10 days. Nuclei are counterstained with
Hoechst. Arrowheads: multinucleated myotubes.
(B) Graph quantifying the proportion of MyHC+ cells using z stack confocal microscopy of three hPSC lines shown in (A).
(C) Immunolabeling for LAMININ (extracellular matrix), MyHC, and nuclei (Hoechst) on DMD artificial muscles.
(D) Western blot for MyHC (250 kDa) in undifferentiated and 3D differentiated iPSC-derived, inducible myogenic cells. b-tubulin: loading control (50 kDa).
(E) qRT-PCR analysis of artificial muscles for myogenic markers. DYSTROPHIN (DYS) is absent from DMD-derived artificial muscles. N = 3 for all lines apart from
LMNA mutant and LGMD2D hiPSCs, whose error bars represent intra-experimental replicates (n = 3). Values are normalized on GAPDH expression; DDCt is
calculated on the corresponding expression values of undifferentiated cells.
(F) Immunohistochemistry for sarcomeric actin in DMD artificial muscles after 10 days of differentiation.
(G) Transmitted electron microscopy images of DMD iPSC-derived artificial muscle showing sarcomeres (white arrowheads: z lines).
(H) Immunofluorescence showing PAX7+ nuclei adjacent to DESMIN+ myofibers following transgene-free commitment and differentiation of hiPSCs in 3D for
14 days. The graph quantifies the percentage of PAX7+ nuclei within the hydrogels (a total of 5,341 nuclei across 10 random fields).
(I) Bright-field image of a tibialis anterior (TA) muscle 1 week after implantation of artificial muscles generated using GFP+ myogenic cells. Dashed rectangle:
grafted area.
(J) Immunofluorescence showing engrafted human nuclei (LAMIN A/C+, left) corresponding to an area in a serial section with embryonic MyHC+ (eMyHC) fibers in
transverse sections of a TA muscle 1 week after implantation. Right graphs show quantification of human nuclei from three healthy or dystrophic cell lines; N = 6,
2 mice/cell type; mean ± SD: hESCs 92 ± 30, hiPSCs 59 ± 19, DMD hiPSCs 1,068 ± 132.
(K) Immunofluorescence of systemically delivered 594-conjugated IB4 isolectin (red) labeling endothelial cells within the implanted human artificial muscle
(LAMIN A/C: human nuclei).
Error bars: mean ± SD. Scale bars: (A) top 250 mm, bottom 25 mm; (C, F, and K) 100 mm; (G) 1 mm; (H) 20 mm; (I) 1 mm; (J) 200 mm. For additional information, see
Figures S1 and S2.whether our 3D platform generated and provided a niche for
Pax7+ cells, we induced myogenic commitment and differentia-
tion of transgene-free hiPSC-derived myogenic progenitors
directly in hydrogels. This resulted in PAX7+ cells juxtaposed tomyofibers, albeit with variability among the tested hiPSC lines
(Figure 2H).
To further characterize hPSC-derived artificial muscles,
they were implanted into immunodeficient mice. Tibialis anteriorCell Reports 23, 899–908, April 17, 2018 901
Figure 3. hiPSC-Derived Artificial Skeletal Muscles Model Skeletal Muscle Laminopathies
(A) Confocal (z stacks merge) whole-mount immunofluorescence for DESMIN (myotubes), LAMIN A/C, and EMERIN (nuclear lamina) on hiPSC-derived (healthy
and LMNA mutant) artificial muscles. Hoechst: nuclei.
(legend continued on next page)
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(TA) muscles of non-obese diabetic (NOD)-severe combined
immunodeficiency (SCID)-gamma mice (NSG) (N = 24) were
injured, and a strip of host tissue was replaced with GFP-ex-
pressing hPSC-derived artificial muscles. GFP+ implants were
identifiable in explanted TA muscles at various time points
(Figures 2I and S2A), suggesting successful engraftment. Trans-
verse sections of implanted muscles showed engraftment of
human cells, highlighted by the widespread presence of human
LAMIN A/C+ nuclei (Figures 2J and S2B). LAMIN A/C+ areas co-
localized with embryonic MyHC+ (eMyHC) fibers, demonstrating
skeletal muscle generation in vivo (Figures 2J, S2C, and S2D).
Engraftment was confirmed by expression of human muscle-
specific transcripts in implanted muscles, and blood vessels
within the implants were detected by immunolabeling for CD31
(Figures S2E–S2G). We further investigated vascularization of
the artificial muscle by systemically injecting fluorescent isolec-
tin into the mouse circulation before harvesting implanted mus-
cles. Isolectin+ vessels were evident within the implant, confirm-
ing functional vascularization (Figure 2K).
Therefore, fibrin hydrogels under uniaxial tension stimulate
efficient and aligned 3D skeletal myogenic differentiation of
healthy and dystrophic hPSCs. Muscle constructs recapitulate
distinctive molecular, structural, and functional features of skel-
etal muscle and engraft in immunodeficient mice.
hiPSC-Derived Artificial Skeletal Muscles Enable
Disease Modeling of Skeletal Muscle Laminopathies
Organoids have great potential for disease modeling and drug
development, so we examined whether our organoid-like, artifi-
cial skeletal muscle could model severe and incurable forms of
muscular dystrophy. We also hypothesized that the 3D nature
of our hydrogels would facilitate detection of pathological hall-
marks less evident in standard bi-dimensional cultures. To inves-
tigate this, we examined artificial muscles generated from hiPSC
derived from patients with muscular dystrophies caused by mu-
tations in the LMNA gene. LMNAmainly encodes the A-type lam-
ins, lamin A and lamin C (LAMIN A/C), nuclear envelope proteins
that assemble with B-type lamins into the nuclear lamina,
providing structural support and regulating gene expression
(Worman, 2012). LMNA mutations cause a plethora of diseases
called laminopathies, of which three forms affect skeletal muscle
(Maggi et al., 2016): limb-girdle muscular dystrophy type 1B
(LGMD1B), autosomal dominant Emery-Dreifuss muscular
dystrophy 2 (EDMD2), and LMNA-related congenital muscular
dystrophy (L-CMD). Abnormalities in nuclear morphology are a
key histological feature of skeletal muscle laminopathies (Park(B) Comparison of confocal 3D nuclear reconstructions of the same iPSC lines sh
constructs (right). Nuclei are immunolabeled for LAMIN A/C.
(C) Box and whiskers graph quantifying nuclear abnormalities in hiPSC-derived a
dystrophies (red color shades) versus 3 control donors (blue color shades). LGMD
nuclear abnormalities. Lower panel: representative images of 3D-reconstructed
0.0022, Mann-Whitney U test. n = 6 in CTRL group and 6 in LMNA mutant group
nuclei/hydrogel/experiment across 8 random high-power fields were scored. Bo
min to max values.
(D) Scatter dot plot of the specific length of the nuclei scored in (C). **p = 0.0022,
populations per group in 2 independent experiments). Each symbol is one nucle
(E) Distribution plot of the graph in (D).
Scale bars: (A and B) 15 mm; (C) 10 mm. For additional information, see Table S1et al., 2009), and using hiPSC-based modeling could provide a
unique, non-invasive tool to address open questions, such
as challenging genotype-phenotype correlations, and develop
new therapeutics (Scharner et al., 2015).
3D artificial muscles were made by differentiating three LMNA
mutant hiPSCs from patients with skeletal muscle laminopa-
thies, referred to by their mutation as LMNA L35P, R249W,
and K32del (Figures 1A, 2A, and 3A). 3D nuclear reconstruction
of mutant LMNA cells differentiated in artificial muscles high-
lighted features less prominent in standard monolayer cultures
(Figure 3B). This prompted us to quantify nuclear abnormalities,
including elongation, deformities, and presence of blebs (Fig-
ure 3C), in LMNA mutant hiPSC-derived artificial muscles. For
controls, we used wild-type (WT) hPSCs and LGMD2D hiPSCs
(Figures 1A and 2A), which have not been reported to have dys-
morphic nuclei (Kirschner and Lochm€uller, 2011). As expected,
nuclei in artificial muscle derived from control cells did not
display significant nuclear abnormalities. In contrast, all mutant
LMNA artificial muscles showed a significant proportion of cells
with nuclear aberrations (p = 0.0022, N = 6) (Figure 3C; Table S1;
Videos S1 and S2).
Nuclear elongationwas a predominant abnormality, in linewith
biopsy-derived primary myoblast 3D cultures (Bertrand et al.,
2014). Measurements confirmed that laminopathic muscle con-
structs contained significantly elongated nuclei compared to
control artificial muscles (p = 0.0022) (Figures 3D and 3E), sup-
porting using this outcome measure in future therapy screening
platforms. Thus, hiPSC-derived artificial muscles recapitulate
cellular hallmarks of skeletal muscle laminopathies with high
fidelity and are amenable to model severe muscle disorders.
Increasing Histological Complexity: Multilineage
hiPSC-Derived 3D Artificial Skeletal Muscles
Skeletal muscle tissue also contains non-muscle support cell
types, such as vascular endothelial cells (ECs) and pericytes
(PCs), which permit blood perfusion while controlling homeo-
stasis of the muscle stem cell compartment (Christov et al.,
2007). Therefore, adding ECs and PCs to artificial muscles could
generate a more physiologically relevant model in vitro and
improve survival of larger constructs in vivo, which require
prompt vascularization to prevent hypoxia-induced cell death
(Criswell et al., 2013; Gholobova et al., 2015; Koffler et al.,
2011; Levenberg et al., 2005). To achieve these aims, we first
derived isogenic ECs and PCs from the same hiPSCs used for
myogenic differentiation (Figure S3A) (Orlova et al., 2014). We
then combined isogenic hiPSC-derived ECs, PCs, andmyogenicown in (A) differentiated as monolayer cultures (left) versus 3D artificial muscle
rtificial muscle generated from 3 patients affected by LMNA-related muscular
2D artificial muscles are included as negative control, because they do not have
nuclei used to score laminopathy versus control muscles in the graph. **p =
(3 cell populations per group in 2 independent experiments). A minimum of 45
xes, 25th to 75th percentiles; horizontal line inside, median; +, mean; whiskers,
Mann-Whitney U test. n = 6 in CTRL group and 6 in LMNAmutant group (3 cell
us. Error bars: mean ± SD.
and Videos S1 and S2.
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Figure 4. Multilineage Artificial Muscles Containing Isogenic hiPSC-Derived Vascular Cells and Motor Neurons
(A) Left panel: whole-mount immunofluorescence of an artificial muscle containing a self-organized isogenic network of hiPSC-derived CD31+ endothelial cells
(arrowheads). Right panel: higher-magnification confocal image of the boxed area showing lateral z views.
(B) Hyper-stack image (12 frames) processed with color-coding on CD31 staining (ImageJ) highlighting the 3D structure of the endothelial network. Frame
thickness: 2 mm.
(C) Confocal images of whole-mount immunolabeling of a multilineage construct containing GFP+ pericytes (PCs), displaying coexistence of myofibers (MyHC),
ECs (CD31), and PCs. Arrowheads: CD31+ ECs juxtaposed to PCs.
(D) Confocal image showing an additional example of a multilineage construct as in (C) with lateral z views. Arrowhead indicates a MyHC+ and GFP+ multinu-
cleated myotube (see Discussion).
(E) Quantification of confocal images of tri-lineage artificial muscles showing the average number of MyHC+ (muscle), GFP+ (PCs), and CD31+ (ECs) nuclei per
0.1 mm2 field. Error bars: SEM. n = 10 images.
(F) Confocal immunofluorescence panel of multilineage 3D artificial muscle derived fromWT hiPSCs containing isogenic myofibers, vascular cells (ECs and GFP+
PCs), and motor neurons (SMI32). Color-coded combination enabled discrimination of the four cell types based upon the color of the merge. Arrowheads
highlight two motor neurons showing multiple axon-like processes.
(legend continued on next page)
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cells within hydrogels under tension and tested media that sup-
ported growth and differentiation of those lineages. After 10 days
in culture, long (up to 0.9 mm) CD31+ vessel-like formations
coexisted in the same 3D environment close to isogenic myo-
fibers (Figure 4A). The 3D nature of EC networks was visualized
through hyper-stack images processed with depth color-coding
for CD31 immunolabeling (Figure 4B). Due to the absence of un-
equivocal PC-specific markers (Armulik et al., 2011), hiPSC-
derived PCs were transduced with a lentivirus encoding for
GFP to allow their detection within artificial muscles. Immuno-
fluorescence demonstrated alignment and coexistence of myo-
fibers, ECs, and PCs within the same 3D environment (Figures
4C–4E). In vivo studies of muscle function in immunodeficient
mice suggested enhanced force recovery only in muscles
receiving multicellular versus single-lineage (i.e., only myofibers)
artificial muscle implants (Figure S3B).
Another key cell type for skeletal muscle is the spinal motor
neuron. Deriving primary human motor neurons is challenging;
however, several protocols are available to differentiate them
from hPSCs (Patani, 2016), including their coculture with primary
myotubes (Steinbeck et al., 2016). Therefore, developing an
isogenic human muscle-motor neurons platform would model
neuromuscular disorders in a personalized fashion. To this aim,
we differentiated hiPSCs into neural progenitors (Stacpoole
et al., 2011) and further adapted our tri-lineage culture system
to enable differentiation of neural precursors into motor neurons.
We obtained stable 3D artificial muscle constructs containing
four distinct isogenic cell types, i.e., myofibers, ECs, PCs, and
SMI32+ cells with long axon-like processes resembling motor
neurons spreading from hiPSC-derived neurospheres placed
above the hydrogels (Figures 4F and 4G).
We next investigated generation of neuromuscular junctions
through muscle-motor neuron bi-lineage models. Interactions
between the two cell types were optimized by employing a differ-
entiationparadigm that generates ahighly enrichedmotor neuron
population (Figure S3C) (Hall et al., 2017) and allows seeding
of single-cell neural precursors within the hydrogel. DMDmuscle
constructs were made containing WT motor neurons, which
showed alpha-bungarotoxin+ acetylcholine receptors and stri-
ated myofibers with the sarcomeric protein Titin (Figures 4H
and 4I), indicating a positive effect on myofibers’ maturation ex-
erted bymotor neurons. Thus, we generated complex, 3D,multi-
lineage, artificial skeletal muscle models from hiPSCs.
DISCUSSION
Use of hPSCs for tissue engineering and complex disease
modeling is expanding, and exciting results have been obtained
with hiPSC-derived organoids (Passier et al., 2016). Here we
show that 3D constructs resembling skeletal muscle tissue can
be generated by differentiating healthy donor and disease-spe-(G) Quantification of the motor neurons (MNs) in quadruple lineage cultures show
(H) Confocal immunofluorescence of a DMD artificial muscle construct containin
(BTX)+ acetylcholine receptors (zoom in).
(I) Confocal immunofluorescence of a sister construct of (H) with aligned, multin
acetylcholine receptors (red signal in white box).
Scale bars: (A and B) 25 mm; (C–F, H, and I) 10 mm. For additional information, scific hPSCs within fibrin hydrogels under unidirectional tension.
We have generated artificial muscles from patients affected by
severe forms of muscle diseases with different genetic inheri-
tance, namely, Duchenne (X-linked), LGMD2D (autosomal
recessive), and LMNA-related (autosomal dominant) muscular
dystrophies. Our hiPSC-derived 3D platform recapitulated nu-
clear abnormalities characteristic of LMNA-related muscular
dystrophies. Nuclear elongation was the most prominent abnor-
mality, consistent with reports using LMNAmutant mice and pri-
mary human myoblasts (Bertrand et al., 2014; Nikolova et al.,
2004), supporting the high fidelity of our 3D platform formodeling
skeletal muscle laminopathies. We also provide proof of princi-
ple of hPSC-derived artificial muscle engraftment, laying the
foundation for in vivo modeling and drug testing in humanized
dystrophic muscles.
A major advantage of using hPSCs for muscle bioengineering
is the ability to derive different cell types from the same cellular
source, and here we provide evidence of generation of isogenic,
multilineage, hPSC-derived artificial skeletal muscles. Although
our data and published work (Rao et al., 2018) indicate that skel-
etal muscle properties can be observed in bundles of hPSC-
derived myofibers, our results further indicate that maturation
of fully functional artificial muscles might require contribution
from other cellular lineages, such as vascular cells and motor
neurons (Christov et al., 2007; Ecob-Prince et al., 1986; Kostallari
et al., 2015; Martin et al., 2015). This could be particularly rele-
vant for in vitro studies of non-muscle-specific defects in muscle
disorders (Dabire´ et al., 2012; Palladino et al., 2013) or to predict
off-target effects of skeletal muscle-directed therapeutics. Artifi-
cial muscles containing vascular cells will likely improve engraft-
ment upon implantation in vivo, via rapid anastomosis with the
host circulation, in line with improved engraftment of vascular-
ized muscle constructs derived from primary myoblasts (Perry
et al., 2017; Quarta et al., 2017). Moreover, multilineage artificial
muscles could also provide insights into human muscle regener-
ation dynamics, because we observed generation of GFP+ myo-
fibers in constructs in which only PCs had been transduced with
a GFP-encoding lentiviral vector (Figure 4D). This suggests
myogenic potential of PCs or their recruitment from differenti-
ating muscle, similar to that described in mice with lineage
tracing experiments (Dellavalle et al., 2011).
This platform can be further engineered to include other plurip-
otent derivatives, such as different muscle interstitial cells (Te-
desco et al., 2017). Nonetheless, bioengineering an all-hPSC-
derived muscle will require highly specialized culture conditions,
potentially with a combination of transgene-based (e.g., Darabi
et al., 2012; Tedesco et al., 2012) and transgene-free (e.g., Caron
et al., 2016; Chal et al., 2015) differentiation methods, because
culture conditions to maintain non-myogenic cells might interfere
with transgene-free, small molecule-basedmyogenic differentia-
tion of hPSCs. Further optimization of artificial muscles includesn in (F). Error bars: SEM. n = 7 images.
g non-isogenic WT SMI32+ motor neurons and showing alpha-bungarotoxin
ucleated myofibers with sarcomeric TITIN+ striations (arrowheads) and BTX+
ee Figure S3.
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improvementofmaturationviachemical, electrical or optical stim-
ulation and scaling down for high-throughput screening. More-
over, culture in autologous fibrinogen (de la Puente and Luden˜a,
2014)would enable a highly personalizedplatform. Finally, human
muscle models would reduce laboratory animal use for toxicity
testing. In conclusion, this hPSC-derived artificial skeletal muscle
platform could bring together regenerative medicine and drug
developmentunder the same translational technology, advancing
knowledgeon thepathogenesis anddevelopment of therapies for
muscle diseases.EXPERIMENTAL PROCEDURES
Generation of 3D Skeletal Muscle Constructs
15 hPSC lines (1 hESC line + 14 hiPSC lines) and 1 primary humanmyoblast line
were used.Hydrogelswere produced as published (Hansen et al., 2010) and ac-
cording to the manufacturer’s instructions (EHT Technologies, Hamburg).
106 myogenic cells pre-treated with ROCK inhibitor (10 mM; 1–2 hr) were used
per construct (total volume: 120 mL). Artificial muscles were cultured at 37C
with 5% CO2 supplementing the medium with 33 mg/mL aprotinin (Sigma,
A3428) to prevent fibrinogen degradation. To induce myogenic differentiation,
1 mM 4-OH tamoxifen was added 48 hr after polymerization in proliferation me-
diumand then 24hr later in differentiationmedium. For transgene-freemyogenic
differentiation (Genea Biocells), progenitors were cultured for 7 days in commit-
mentmediumbefore cells were combinedwith fibrin, switching to differentiation
medium 2 days later. To generate PAX7+ cells, myogenic commitment was
induced for 2 days in standardmonolayer culture conditions and then continued
in 3D for 5 days before switching to differentiation medium; hydrogels were
cultured for a total of 14 days. Pax7+ cells were observed in 1 of 3 lines
(NCRM1 iPSCs).
Triple-lineage constructs were made with the same method using a mix of
70% myogenic cells (7 3 105) and 30% vascular cells (6 3 104 ECs and
2.4 3 105 PCs). Muscles were cultured in a 1:1 mix of human iPSC-derived
mesoangioblast-like inducible myogenic cells (HIDEM) proliferation medium
(Maffioletti et al., 2015) and endothelial medium A (EC-SFM [endothelial
cell-serum-free basal medium]; 1% platelet-poor, plasma-derived serum;
30 ng/mL vascular endothelial growth factor [VEGF]; 20 ng/mL basic fibroblast
growth factor [bFGF]) for 48 hr and then in a 1:1 mix of HIDEM differentiation
medium (Maffioletti et al., 2015) and endothelial medium B (Lonza, CC-3162)
after the second tamoxifen administration. Muscles were cultured for
10 days at 37C with 5% CO2, changing the medium every other day. Human
fibrinogen was kindly provided by Prof. H. Redl (LBG, Vienna).
Constructs containing four lineages (muscle + ECs + PCs + motor neurons)
were made as described earlier; after 1 hr of polymerization, 6 neurospheres
(neural progenitor cells [NPCs]) were decanted on top of the hydrogels using
10 mL of fibrin. After the second hour of polymerization, hydrogels were placed
in media containing an equal ratio of Iscove’s Modified Dulbecco’s Medium
(IMDM)-based HIDEM proliferation medium, EC-SFM (Orlova et al., 2014), and
a chemically definedmedium (Stacpoole et al., 2011), supplemented with hepa-
rin (5mg/mL) and retinoic acid (0.1mM).NPCdifferentiation tomotor neuronswas
achieved through supplementation of themediawith retinoic acid for 7 days and
then with retinoic acid and purmorphamine (1 mM) until fixation at day 14.
To produce hydrogels containingmyofibers (70%) and single-cell motor neu-
rons (30%) (derived as per Hall et al., 2017), constructs were cultured for 48 hr
using a 1:1 mix of HIDEM proliferation medium with 1% fetal bovine serum
(FBS) and neural precursormedium (Shi et al., 2012). The samemixwas supple-
mentedwith4-OH tamoxifen and0.1mMg-secretase inhibitor (Sigma, L1790) to
inducemyogenic andneural differentiation. After 24 hr,mediumwaschanged to
administer the second tamoxifen pulse. Hydrogels were kept in culture for
15 days at 37C with 5% CO2, changing the medium mix with 0.1 mM g-secre-
tase inhibitor every day. At day 5, the medium was supplemented with agrin
(R&D Systems, 550-AG/CF) to promote neuromuscular junction formation.
Agrin concentrations of 0.1, 0.5, and 1 nM were used over the 3 initial days,
and the final concentrationwas kept until fixation of constructs. Additional infor-
mation can be found in Supplemental Experimental Procedures.906 Cell Reports 23, 899–908, April 17, 2018Analysis of Nuclear Abnormalities in LMNAMutant Artificial Muscles
LMNA mutant iPSCs derived from three patients affected by skeletal muscle
laminopathies (LGMD1B and L-CMD) were provided by Cellular Dynamics
International (CDI; http://www.cellulardynamics.com) and Cure Congenital
Muscular Dystrophy (CureCMD; http://www.curecmd.org). iPSCs were
derived by CDI using episomal vectors from samples provided by CureCMD,
which holds patients’ clinical information. Pluripotency was tested by CDI
with a proprietary set of genes. LMNA mutant iPSCs had three heterozygous
dominant mutations: p.K32del and p.L35P located in LMNA exon 1 and
p.R249W in LMNA exon 4.
Hydrogels were fixed with 4% paraformaldehyde (PFA) for 3 hr at 4C fol-
lowed by 6 hr of blocking at 4C (10% FBS, 1% BSA, and 0.5% Triton X-100
in 0.05 M Tris-buffered saline [TBS]) before immunolabeling with rabbit anti-
Desmin (1:150) (Sigma, D8281), mouse anti-LAMIN A/C (1:100) (Novocastra
NCL-LAM), and goat anti-Emerin (1:50) (Santa Cruz, sc8086) antibodies
overnight at 4C in TBS, 1% BSA, and 0.5% Triton X-100. The next day, hy-
drogels were washed with TBS 6 times hourly and incubated overnight with
Hoechst 33342 (Sigma, B2261) plus species-specific secondary antibodies
(Alexa Fluor 488, 546, and 647) (Thermo Fisher Scientific). The following
day, hydrogels were washed 6 times with TBS and embedded in mounting
medium (Dako, S3023A) on glass slides. A confocal microscope (Leica,
SPE2) was used for imaging, using 953 magnification to take 5 to 9 z stacks
(step size: 0.5 mm) of randomly selected regions (final thickness: 12–82 mm).
The z stacks were 3D reconstructed and analyzed based on LAMIN A/C im-
munolabeling using Imaris 8.4.1 software (Bitplane). Nuclei were analyzed
by scoring the number of abnormalities per field and by measuring major
axis length. Oval or slightly elongated nuclei were scored as normal. Three
LMNA mutant patients and three controls were quantified. A minimum of
45 nuclei per hydrogel per experiment across 8 random fields was scored.
Reproducibility was validated by 3 independent operators (one researcher
was blinded) (Table S1). Normal distribution of nuclear abnormalities was
tested using the D’Agostino and Pearson test and statistical testing
compared the LMNA mutant group (N = 6; 3 cell populations in 2 experi-
ments) versus the non-mutant group (N = 6; 3 cell populations, 2 experi-
ments) using Mann-Whitney U test, because one cell population per group
did not have a normal distribution of values.
Ethics
Work with human cells was performed under approval of the National
Health Service (NHS) Health Research Authority Research Ethics Commit-
tee (reference No. 13/LO/1826) and Integrated Research Application
System (IRAS) project (ID No. 141100) and, for motor neuron work, accord-
ing to approved regulations and guidelines by University College London
Hospital’s National Hospital for Neurology and Neurosurgery and University
College London’s (UCL) Institute of Neurology joint research ethics commit-
tee (09/0272). Use of hESCs was approved by the Steering Committee for
the UK Stem Cell Bank and for the use of stem cell lines (SCSC12-46 and
SCSC13-14). Procedures involving animals were approved by the UK Home
Office according to Animals (Scientific Procedures) Act (ASPA) regulations
and performed under PPL 70/8566.
Statistics
Values are mean ± SD or SEM (as specified). Specific N or n values and statis-
tical tests are indicated in figure legends. Data were analyzed with Microsoft
Excel and GraphPad Prism.
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